Completion Rate and Side-Effect Profile of Three-Month Isoniazid and Rifapentine Treatment for Latent Tuberculosis Infection in an Urban County Jail
Open Access
- 1 January 2016
- journal article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 3 (1), ofv220
- https://doi.org/10.1093/ofid/ofv220
Abstract
In an urban jail population, 3 months of isoniazid and rifapentine (3HP) was associated with an 85% latent tuberculosis infection treatment completion rate compared with 18% in a standard 9-month isoniazid treatment group. Among the 91 patients who started 3HP therapy, there were 2 treatment discontinuations from adverse drug reactions.Keywords
Funding Information
- Council of State and Territorial Epidemiologists
- Applied Epidemiology Fellowship Program
This publication has 10 references indexed in Scilit:
- Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United StatesThe International Journal of Tuberculosis and Lung Disease, 2013
- Outbreak of Tuberculosis Associated with a Newly Identified Mycobacterium tuberculosis Genotype — New York City, 2010–20132013
- Trends in Tuberculosis — United States, 20122013
- Isoniazid preventive therapy in correctional facilities: a systematic review [Review article]The International Journal of Tuberculosis and Lung Disease, 2012
- Three Months of Rifapentine and Isoniazid for Latent Tuberculosis InfectionNew England Journal of Medicine, 2011
- Weekly Rifapentine/Isoniazid or Daily Rifampin/Pyrazinamide for Latent Tuberculosis in Household ContactsAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Incidence of TB in Inmates with Latent TB Infection: 5-Year Follow-upAmerican Journal of Preventive Medicine, 2005
- Jails, a neglected opportunity for tuberculosis preventionAmerican Journal of Preventive Medicine, 2005
- Tuberculosis outbreak in a Texas prison, 1994Epidemiology and Infection, 1996